AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil/Mycophenolic Acid
Description: MMF/MPA will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil/Mycophenolic Acid
Description: MMF/MPA will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone IV will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone IV will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per schedule specified in the respective arm.
Study NCT02550652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered as per schedule specified in the respective arm.
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental MWM
Description: Mobilization with Movement
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental MWM
Description: Mobilization with Movement
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental MWM
Description: Mobilization with Movement
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force
Study NCT03079804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force
Study NCT04298528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5mg 2 times a day for 30 days after total knee replacement
Study NCT04298528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times a day for 30 days after total knee replacement
Study NCT01511887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ibuprofen
Description: 10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
Study NCT03970109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637
Description: 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
Study NCT03970109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT02442830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Video Capsule Endoscopy
Description: The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue.
Study NCT01412775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short-term group intervention program
Description: The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration.
Study NCT04118322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy (peppermint oil)
Description: The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)
Study NCT02682420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: everlinQ endoAVF System
Study NCT03273036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Triamcinolone acetate 1 cc
Description: 40 mg Triamcinolone acetate 1 cc
Study NCT03273036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: no injected agent
Study NCT02877550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
Study NCT02877550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: p.o. once daily according to dose level (DL) or MTD
Study NCT01252459 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
Study NCT01252459 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
Study NCT03747081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
Study NCT03747081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
Study NCT00983814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa+Carbidopa
Description: 3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
Study NCT00983814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droxidopa+Carbidopa
Description: 3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
Study NCT02541240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience Curriculum
Description: The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
Study NCT04891679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral misoprostol solution (OMS)
Description: Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.
Study NCT01891734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy plus Moving Forward
Description: All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
Study NCT01891734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
Study NCT00220818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study NCT00220818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study NCT01312467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Study NCT04431232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation
Description: Band ligation of the gastric body for weight loss
Study NCT00132444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical vaginal application of UC-781 gel
Description: UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
Study NCT00132444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical vaginal application of UC-781 gel
Description: UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
Study NCT02788175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Entyvio (Vedolizumab)
Description: A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
Study NCT05226650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular meal pattern
Description: 6 meals every day
Study NCT05226650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irregular meal pattern
Description: It consists of consuming a different number of meals every day (between 3 and 9).
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM)
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Description: 0.5 mL, IM
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, IM
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: 0.5 mL, IM
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular (IM)
Study NCT02461147 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy with intraoperative cholangiogram
Description: cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
Study NCT03004430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Silent mantra meditation with spiritual mantra
Study NCT03004430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation
Study NCT00661960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 400mg tablet twice daily by mouth for nine months
Study NCT00661960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600mg capsule once daily by mouth without regard to food
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, IM
Study NCT02199691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: 0.5 mL, IM
Study NCT01294618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.
Description: Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
Study NCT01062685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy assessment
Description: The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes.
Study NCT03581136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose Fractionation
Description: Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
Study NCT06620926 — intervention group
Intervention type: OTHER
Intervention: IDH mutant-type
Description: The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
Study NCT06620926 — intervention group
Intervention type: OTHER
Intervention: IDH wild-type
Description: The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
Study NCT00120380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized iloprost
Study NCT00120380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01046955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Description: comparison of induction therapies.
Study NCT03609294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Fimasartan, Linagliptin)
Description: Co-administration of Fimasartan and Linagliptin
Study NCT03609294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Fimasartan/Linagliptin)
Description: Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
Study NCT02344368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
Study NCT02344368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
Study NCT05750641 — intervention group
Intervention type: OTHER
Intervention: removing milk and dairy products from diets without medical treatment
Description: A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
Study NCT05750641 — intervention group
Intervention type: OTHER
Intervention: According to current standard algorithms and guidelines, appropriate treatment for FD types.
Description: According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
Study NCT04486287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy.
Study NCT02078739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Program at home using internet technology
Study NCT02078739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program at home using internet technology
Study NCT01581593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kedrion IVIG 10%
Description: Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
Study NCT01138748 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: hypofractionated radiation therapy
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin Suppository
Description: Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin Suppository
Description: Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.